6236-97-1
Chemical Structure
CK-102
- CAS No.: 6236-97-1
- Formula:C15H13NO
- Molecular Weight:223.28
IUPAC Name: 3,4-dimethylacridin-9(10H)-one
InChIKey: ZRMNUBSZWKYSME-UHFFFAOYSA-N
SMILES: O=C1C=2C=CC=CC2NC=3C1=CC=C(C3C)C
Biological Activity: CK-102 is an interleukin-1 (IL-1) inhibitor. CK-102 reduces mRNA synthesis. CK-102 does not inhibit DNA synthesis. CK-102 only slightly inhibits protein synthesis, or has no effect on it. CK-102 delays wound healing after ophthalmic surgery and prolongs the failure time of trabeculectomy fistulas. CK-102 inhibits lens protein-induced ocular inflammation at both early and late stages. CK-102 inhibits endotoxin-induced uveitis. CK-102 does not inhibit interleukin-1-induced uveitis. CK-102 can be used in research related to glaucoma filtration failure and uveitis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CK-102 | CK-102 is an interleukin-1 (IL-1) inhibitor. CK-102 reduces mRNA synthesis. CK-102 does not inhibit DNA synthesis. CK-102 only slightly inhibits protein synthesis, or has no effect on it. CK-102 delays wound healing after ophthalmic surgery and prolongs the failure time of trabeculectomy fistulas. CK-102 inhibits lens protein-induced ocular inflammation at both early and late stages. CK-102 inhibits endotoxin-induced uveitis. CK-102 does not inhibit interleukin-1-induced uveitis. CK-102 can be used in research related to glaucoma filtration failure and uveitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen Z, et al. Inhibitory effects of interleukin-1 blockers on corneal fibroblast proliferation. J Ocul Pharmacol Ther. 1996;12(2):169-182. [Content Brief]
- [2]. Schwade ND, et al. Effects of interleukin-1 blockers on ophthalmic wound healing in a rabbit model of trabeculectomy. J Ocul Pharmacol Ther. 1995;11(2):125-134. [Content Brief]
- [3]. Chiou GC, et al. Prevention and treatment of ocular inflammation with a new class of non-steroidal anti-inflammatory agents. J Ocul Pharmacol. 1994;10(1):335-347. [Content Brief]
